CAMBRIDGE

Cambridge University Press
978-1-107-07458-3 - Cognitive Impairment in Major Depressive Disorder: Clinical Relevance, Biological Substrates and Treatment Opportunities
Edited by Roger S. McIntyre
Index
More information

Index

Locators in **bold** refer to figures and tables

ABM (attention bias modification), 268
absolute ceiling effect, assessment, 235
abuse, childhood, 5. *see also* childhood trauma
academic functioning. *see* educational functioning
action-based cognitive remediation (ABCR), **315**, 316, **317**
activities of daily living (ADL), 16, 161
activity scheduling, cognitive remediation, 315, 316
acute clinical stage, inflammation, 163, **164**
AD. *see* Alzheimer's disease
ADHD. *see* attention deficit/hyperactivity disorder
adherence to treatment, 161
  clinician–patient relationship, 42, 43
  and cognitive dysfunction, 32–33
  exercise, 333
  functional outcomes, 140
adolescent depression. *see* pediatric depression
Advanced Finances Task (AFT), 139
aerobic exercise. *see* exercise
affective neuroscience, 257
age of onset, 1, 113, 117, 119. *see also* late-onset MDD
agitation. *see* psychomotor speed
AIC (anti-inflammatory cytokines), 162
alcohol intoxication, 18, **19**, 20
algorithms, assessment, 37
alternative medicine, 275, **286**
Alzheimer's disease (AD), 16, **17**, **18**, 24, 237
  insulin resistance, 214, 215, 216
American Academy of Child and Adolescent Psychiatry (AACAP), 47
amphetamine, 23
amygdala
  anatomy, 63
  biological mechanisms of MDD development, 5–6
  biomarkers of illness, 149, 153, 154
  emotional processing, 83, 202, 263, 264
  inflammation, 168, 169
  negative cognitive bias, 202
  neural circuits, 197
  post-recovery deficits, 111
  progressive cognitive deficits, 117
  rumination, 202–203
  social emotional processing, 83, 93, **96**
  social exclusion, 88
anatomy of brain, 60–66, 116–117
anhedonia, 83, 84
animal studies, erythropoietin, **292**, 293
ANT (Attention Network Task), **49**–**50**, 51
antecedents to illness. *see* predictions of future depression; premorbid cognitive function
anterior cingulate cortex. *see* cingulate cortex
anticholinergic effects, medication, 283. *see also* tricyclic antidepressants
antidepressant medication, 275–280, **278**, 283
  amygdala, 197
  baseline cognitive function, 274
  biomarkers of illness, 74, 151
  combined with CBT, 274
  effects on cognitive dysfunction, 160, 275
  emotional processing, 264
  erythropoietin, 291
  functional outcomes, 126
  hot cognition, 72, 73
  insulin resistance, 213
  neurotoxicity hypothesis, 119, 120
  novel/fast-acting, 74–76
  response to treatment, 169, 260
  social cognition, 106
  see also SNRIs; SSRIs; tricyclic antidepressants
antiglucocorticoid medication, 188
anti-inflammatory cytokines (AIC), 162
anti-inflammatory treatments, 162
  erythropoietin, 293
  insulin treatment, 282–283
anxiety disorders, 39, 64–65, 83
apoptosis, 117, 293
Applied Cognition-General Concerns (ACGC) Scale, 250
arithmetic, 261, 309–310
ARTIST study, pain comorbidity, 39
ASRS (Attention Deficit Hyperactivity Disorder Self-Report Scale), 280
assessment, indications for, 35–37. *see also* measurement
astrocytes, 61–62
attention, 1
  age of illness onset, 113
  biomarkers of illness, 147, **147**, 149, 150–151
  clinician–patient relationship, **42**
  and functional outcomes, **129**–**134**, 258–260
  measures, 229–230, 231
  negative cognitive bias, 201–202
  neural circuits, 199, 201–202
  number of lifetime depressive episodes, 116
  objective measures, **36**
  pediatric depression, 48–52
  post-recovery deficits, 111
  predictive validity of deficits, 15–17, **17**
  psychotherapy, 119–120
  and rumination, 264–265
  three-component model, 6
  treatment interventions, 275–276
  see also cold cognition
attention bias modification (ABM), 268
Attention Control Training Intervention, 309
attention-deficit/hyperactivity disorder (ADHD)
  antecedents to illness, 3–5, 8, **8**–**11**
  white matter integrity, 65
  working memory, 71
Attention/Deficit Hyperactivity Disorder Self-Report Scale (ASRS), 280
Attention Network Task (ANT), **49**–**50**, 51

© in this web service Cambridge University Press www.cambridge.org

CAMBRIDGE

Cambridge University Press
978-1-107-07458-3 - Cognitive Impairment in Major Depressive Disorder: Clinical Relevance, Biological Substrates and Treatment Opportunities
Edited by Roger S. McIntyre
Index
More information

Auditory Verbal Learning Test (AVLT), 55
Australian study, alcohol intoxication, 18–20, **19**
autism, social cognition, 92
autonomic nervous system, and insulin resistance, 210

BAC (blood alcohol concentration), 18–19, **19**
baseline cognitive function
  and antidepressant medication, 274
  measures, 237
  primary care, 37, 41
basolateral nucleus (BLA), amygdala, 168
BBB (blood–brain barrier), 61–62, 289, 291
BDNF. *see* brain-derived neurotrophic factor
BDQ (Brief Disability Questionnaire), 128, 135
Beck Depression Inventory (BDI), 32–33, **33**
Beck model. *see* cognitive model of depression
Behavior and Symptom Identification Scale (BASIS-32), 138
behavioral inhibition. *see* response inhibition
behavioral treatment interventions. *see* cognitive behavioral therapy; cognitive remediation therapy; diet; exercise
benzodiazepines, 40, 118
bias, memory, 265, 268–269. *see also* negative cognitive bias
biofeedback, 266
biological models. *see* neurobiology of depression
biomarkers of illness, 145, **147**, **150**, 151–154
  antidepressant medication, 151
  cytokines, 169
  default mode network, 217
  dehydroepiandrosterone, 183
  early morning cortisol, 74
  endophenotypes, 145–146, 147–148, 149
  epiphenomena, 148, 151–154
  fractional anisotropy, 64–65, 66
  glial cells, 61–62
  hippocampal volume, 63
  hot vs. cold cognition, 70
  insulin resistance, 213
  neuroimaging/genetic, 146
  oxytocin, 88
  pediatric depression, 55, 56
  symptomatic and remitted stages, **147**, **150**, **160**
  white matter neurobiology, 203
bipolar disorder
  antecedents to illness, 5
  attention and processing speed, 260
  biomarkers of illness, 153
  cellular anatomy, 62
  erythropoietin, **300**
  HPA axis, 184–185, **186**
  insulin treatment, 282–283
  progressive cognitive deficits, 116
  white matter integrity, 65
blood alcohol concentration (BAC), 18–19, **19**
blood–brain barrier (BBB), 61, 289, 291
blood flow to brain. *see* cerebral blood flow
blood lipids, and insulin resistance, 210, 213, 215
blood oxygen level detection (BOLD), 61
body language, 92, 102, 106. *see also* social cognition
body mass index (BMI), 330
bottom-up process, hot cognition, 70, 73
BPI (Brief Pain Index), 38
brain anatomy, 62–64, 116–117
brain connectivity. *see* neural connectivity
brain-derived neurotrophic factor (BDNF)
  biomarkers of illness, 146
  erythropoietin, 289
  exercise effects, 329, 332–333
  HPA axis, 187
  progressive cognitive deficits, 117
brain function, 5–6, 60
  biomarkers of illness, 153
  cognitive remediation, **314**
  and insulin resistance, 211, 215–217
  pediatric depression, 52–53
  reward processing, 54–55
  self-focus, 84–85
  social and emotional brain, 82
  see also neural connectivity; neurobiology of depression; neuroscience of functional outcomes
brain injury, cognitive remediation, 306, 319
brain size, and cognitive dysfunction, 63–64
brain structure, chronic exercise effects, 329, 330
bridging activities, cognitive remediation, 315
BRIEF-A self-report scale, 281
Brief Disability Questionnaire (BDQ), 128, 135
Brief Pain Index (BPI), 38
British Columbia Cognitive Complaints Inventory (BC-CCI), 246–247, **247**, **251**
Brixton Spatial Anticipation Test, 232
bupropion, 276

calcium homeostasis, 210
  California Verbal Learning Test (CVLT), 152, 276
CAM. *see* complementary alternative medicines
Cambridge Cognitive Examination-Revised (CAMCOR), 2, **9**
cancer risks, erythropoietin, 301
CANTAB (Cambridge Neuropsychological Test Automated Battery), 70, 71, 117, 232
  functional outcomes, **131**, **133**, 138
  quality of life, 137
cardiovascular disease, 113, 209
case finding approach, primary care, 37
CAT (computerized adaptive testing), 250
catastrophic response, to negative feedback, 72
catastrophizing
  cognitive dysfunction, 245
  insomnia comorbidity, 40
  see also negative cognitive bias
catecholamines, 328. *see also* dopamine; norepinephrine; serotonin
caudate, 263
causation, cognitive dysfunction, 153
CBB (CogState Brief Battery), 21
CBT. *see* cognitive behavioral therapy
CCN. *see* cognitive control network
CDQ (Cognitive Dysfunction Questionnaire), 250
cellular anatomy, brain, 61–62, 65
central nucleus (CeA), amygdala, 168
central tendency, cognitive dysfunction, 237
cerebral autosomal dominant arteriopathy, subcortical infarcts, and leukoencephalopathy (CADASIL), 200
cerebral blood flow
  endophenotypes, 147
  insulin resistance, 210
changes over time, 25
  self-report instruments, 245
  significance of, 23
childhood trauma
  biological mechanisms of MDD development, 5–6
  biomarkers of illness, 152
  HPA axis stress response, 185
  physical and sexual abuse, 6
  see also neurodevelopmental abnormalities; stress

© in this web service Cambridge University Press www.cambridge.org

CAMBRIDGE

Cambridge University Press
978-1-107-07458-3 - Cognitive Impairment in Major Depressive Disorder: Clinical Relevance, Biological Substrates and Treatment Opportunities
Edited by Roger S. McIntyre
Index
More information

children. *see* pediatric depression
Choice Reaction Time (CRT) task, **36**, 231
chronic fatigue syndrome (CFS), 182
cingulate cortex, 147
  anatomy, 63
  attentional bias, 201–202
  biological mechanisms of MDD development, 5–6
  deep brain stimulation, 76
  emotion perception, 263
  neural circuits, 199
  neuroscience of functional outcomes, 259
  pain, 38
  pediatric depression, 53
  progressive cognitive deficits, 117
  self-focus, 85
  social cognition, **96–99**
  social exclusion, 86, **87**, 88
  working memory and executive function, 262
citalopram, 106
clinical outcomes, 73, 140. *see also* functional outcomes and recovery
clinician–patient relationship, primary care, 41–43
coding tasks, 230
cognition
  cytokine effects, 165–166
  definitions, 60
  emotion linkage, 149, 152, 153
  HPA axis, 180–182, 185–187, **186**
  insulin resistance, 211
  see also social cognition
cognitive activation, 307–308
cognitive remission. *see* remission
Cognitive and Physical Functioning Questionnaire (CPFQ), 35, 247–248, **251–252**
cognitive behavioral therapy (CBT)
  combined with antidepressant medication, 274
  HPA axis, 187
  neuroscience of functional outcomes, 268
  progressive cognitive deficits, 120
  response to treatment, 182
cognitive control network (CCN), 258, 263, 268
  attention and processing speed, 259
  emotion perception, 263
  and treatment targets/outcomes, 266
  working memory and executive function, 261
cognitive distortions. *see* negative cognitive bias
Cognitive Drug Research (CDR) computerized assessment system, 277
cognitive dysfunction in MDD, 64–65, 242–244, **243**
  biomarkers of illness, 147–154, **147**, **150**
  and brain size, 63, 64
  clinical significance, 16
  efficacy of treatment interventions, **284–285**
  and functional outcomes, 128, **129–134**
  measures, 233, **234**
  neural correlates, 60, 64
  pediatric studies, **49–50**
  self-report instruments, 34. *see also* Perceived Deficits Questionnaire
Cognitive Dysfunction Questionnaire (CDQ), 250
cognitive efficiency. *see* processing speed
cognitive flexibility, 48, 52, 232, 308. *see also* executive function; neuroplasticity
Cognitive Impairment Associated with Schizophrenia (CIAS), 237
cognitive-interpersonal vulnerability to depression models, 265
cognitive model of depression, 72, 149, 201
  and emotion distortion and biases, 258, 264
cognitive neuropsychological model of depression, 149, **150**
cognitive neuroscience, distinction from affective neuroscience, 257
cognitive reappraisal, 265
cognitive remediation (CR), 266, 306–307
  brain function model, **314**
  evidence-based studies, **313**, 314
  future directions for study, 318–319
  HPA axis, 188
  medication interactions, 318
  motivational issues, 317–318
  pillars of treatment, 307–309
  pseudospecificity of treatment response, 318
  psychotherapy model, **314**, 315–316, **315**, **317**
  rationale for using with MDD, 309
  symptom profiles, 317
  treatment interventions, 282, **284–286**
cognitive reserve, 3. *see also* IQ
cognitive therapies, 197. *see also* cognitive behavioral therapy
CogState Brief Battery (CBB), 21
Cohen's d values, 16, **17**, 20, **21**, **71**
cold cognition, 257
  antecedents to illness, 3, 4, 5, 6, **8–11**
  clinician–patient relationship, 41, **42**
  cognitive alterations during course of illness, 69–76
  combination treatments, 274
  neural circuits, 70
  neuroanatomy, 60
  novel/fast-acting medication, 75
  pediatric depression, 48, 51, 52
  psychological interventions, 154
  screening tools in primary care, 32–34, **33**
  as trait biomarkers, 70, **71**, 74
comorbidity
  addressing in primary care, 31, 32
  assessment in primary care, 37–40
  cardiovascular, 113
  cognitive remediation, 317
  functional outcomes, 140
  pediatric depression, 56
complementary alternative medicines (CAM), 275, **284–286**
compliance. *see* adherence to treatment
computer-assisted cognitive remediation, 307–308, 311, 312
computerized adaptive testing (CAT), 250
computerized assessment instruments, 126
concentration, 15, **131**, 147
confounding factors
  erythropoetin, 294
  measures of cognitive dysfunction and change, 236, 237
  medication, 63, 117
  pediatric illness, 56
  progressive cognitive deficits, 117
connectivity, brain. *see* neural connectivity
Continuous Performance Test (CPT), **49**, 51
Controlled Oral Word Association Test, 232
cortico-limbic circuits, 153
corticosteroids, 183, 184. *see also* hypocortisolism
cortico–striatal–pallidal–thalamic circuits, 198
cortisol levels
  biomarkers of illness, 55, 74
  salivary, 55, 180
  social exclusion, 86
CPFQ (Cognitive and Physical Functioning Questionnaire), 35, 247–278, **251–252**
CPT. *see* Continuous Performance Test

© in this web service Cambridge University Press www.cambridge.org

CAMBRIDGE

Cambridge University Press
978-1-107-07458-3 - Cognitive Impairment in Major Depressive Disorder: Clinical Relevance, Biological Substrates and Treatment Opportunities
Edited by Roger S. McIntyre
Index
More information

CR. *see* cognitive remediation
CRH-R1 (CRH receptor 1 gene), 183–184
CRT (Choice Reaction Time) task, **36**, 231
cumulative number of episodes. *see* number of lifetime depressive episodes
cyberball paradigm, social exclusion, 86, 88
cytokine models of depression and cognition, 162
  amygdala, 165, 168–169
  molecular mechanisms, 165–166
  neurodegenerative effects, 166–167
  see also inflammation

data analysis, measures of cognitive dysfunction, 237–239
DDS (Denver Development Screening Test), 5
decision-making, DSM criteria, 15
declarative memory, 112, 181
deep brain stimulation (DBS), 76, 281
default mode network (DMN), 82, **87**
  insulin resistance, 217–219, **219**
  neuroscience of functional outcomes, 258, 267, 268
Deficits in Executive Function Scale (DEFS), 4
definitions
  cognition, 60
  emotions, 81
  epiphenomena, 151
  executive function, 261
  exercise, 321–322
  social cognition, 102, 106
  social processes, 82
  working memory, 261, 325
dehydroepiandrosterone (DHEA), 183, 188
dementia
  prodromal phase, 119, 235
  and progressive cognitive deficits, 110, 118–120
  social cognition, **96–99**
  see also Alzheimer's disease
DEMO trial, exercise, 332, 333
demyelination, 195
Denver Development Screening Test (DDS), 5
developmental abnormalities. *see* neurodevelopmental abnormalities
dexamethasone suppression test (DST), 183, 184, **186**
DHEA (dehydroepiandrosterone), 183, 188
diabetes, 209. *see also* insulin resistance
Diagnostic and Statistical Manual of Mental Disorders (DSM-5), 1, 15, 69, 147
diary techniques, 86
diet, treatment interventions, **284–285**
diffusion-tensor imaging (DTI), 61, 64
Digit Span Test, 334
Digit Symbol Substitution Test (DSST), **36**, 230, 238, 277, 278, 279
distortions, cognitive. *see* negative cognitive bias
diurnal patterns of cognitive dysfunction, 236
divided attention, 258, 260. *see also* attention
DLPFC. *see* dorsolateral prefrontal cortex
DMN. *see* default mode network
dmPFC (dorsomedial prefrontal cortex), 267
donepezil, 23
dopamine, 328
dopamine reuptake inhibitors, 75
dorsal anterior cingulate cortex. *see* cingulate cortex
dorsolateral prefrontal cortex (DLPFC), 147
  attentional bias, 201–202
  biological mechanisms of MDD development, 5–6
  biomarkers of illness, 149, 153
  emotional processing, 202
  neuroscience of functional outcomes, 259
  self-focus, 84, 85
  social exclusion, **87**
dorsomedial prefrontal cortex (dmPFC), 267
drug treatment. *see* medication
DSST. *see* Digit Symbol Substitution Test
DTI (diffusion-tensor imaging), 61, 64
duloxetine, 275, 277, 279, 280, 283, **284**, **285**, 318
duration of illness
  anatomy of brain, 63
  biomarkers of illness, 152, 153
  and clinical outcome, 73
  and rumination, 265
  see also number of lifetime depressive episodes
dyslipidemia, 210, 213, 215

early intervention
  biomarkers of illness, 73–74
  pediatric depression, 56
  predicting future depression, 8
  and progressive cognitive deficits, 119
  see also treatment interventions
education, patient, 32, 43
educational functioning, 48, 70
  ADHD, 3
  and cognitive dysfunction, 17–20, **18**
  working memory, 71
effect sizes, measures of cognitive dysfunction, 229, **278**
effective ceiling effect, assessment, 235
effort-automatic hypothesis, 152
electroconvulsive therapy (ECT), 281, **285**, 291, 310
emotion network (EN), 258, 267, 268
emotion(s)/emotional processing
  antidepressant medication, 264
  bias, 1, 83, 202, 264. *see also* negative cognitive bias
  brain function, 82
  and cognition, 149, 152, 153
  cytokine model, 165, 166, 168, **170**
  definitions, 81
  erythropoietin, 294, **295–296**, 297, **298**
  neuroscience of functional outcomes, 263–264
  regulation, 82, **87**, 257, 258. *see also* response inhibition
  top-down processes, 197
  see also hot cognition
employment status, 70, 161
  and cognitive function, 16, 17, **18**, 20, **21**, **130**, **131**, **133**
  functional outcomes, 125, 126, 127, 135–137
  primary care clinician–patient relationship, 43
  and progressive cognitive deficits, 119
  working memory and executive function, 262
  see also psychosocial functioning
EN (emotion network), 258, 267, 268
Endicott Work Productivity Scale (EWPS), 280
endophenotypes, 110
  antecedents to illness, 112
  biomarkers of illness, 145–146, 147, 149
enjoyment of life, psychosocial functioning, 138–139
environmental factors
  biomarkers of illness, 153
  measures of cognitive dysfunction and change, 236
epidemiology
  cognitive dysfunction in MDD, 242, **243**
  insomnia comorbidity, 39
  major depressive disorder, 1, 15
  pain comorbidity, 37, 38
  recurrence risk, 257
  youth depression, 47
epigenetics, 146, 185

© in this web service Cambridge University Press www.cambridge.org

CAMBRIDGE

Cambridge University Press
978-1-107-07458-3 - Cognitive Impairment in Major Depressive Disorder: Clinical Relevance, Biological Substrates and Treatment Opportunities
Edited by Roger S. McIntyre
Index
More information

epiphenomena
  cognitive deficit biomarkers of illness, 148, 151–154
  definitions, 151
  see also state vs. trait cognitive dysfunction
episodic memory
  and functional outcomes, **129**
  measures, 229, 231
  predictive validity, 2, 15
Epworth Sleepiness Scale, 40
erythropoietin (EPO), 289, 290–291, **302**
  animal studies, **292**, 293
  clinical limitations, 299–302
  clinical trials, 293–299, **295**–**296**, **298**, **300**
  confounding factors, 294
  future perspectives, 302
  memory, 290, 291, 293, 294, **295**–**296**, **298**, 299, **301**
escitalopram, 275, 312, 318
etiology, cognitive dysfunction, 153
European Study of the Epidemiology of Mental Disorders, 135
evidence-based studies
  cognitive remediation, 309–315, **313**
  exercise, 323, 333
  see also meta-analyses
EWPS (Endicott Work Productivity Scale), 280
exclusion, social, 81, 86, 87, **87**, 88
executive function, 1
  age of illness onset, 113
  biomarkers of illness, **147**, 149
  definitions, 261
  erythropoietin, **295**–**296**, 299
  and functional outcomes, **129**–**134**, 261
  insulin resistance, 209, 211
  measures, 230, 232
  neural circuits, 200
  number of lifetime depressive episodes, 116
  objective measures, **36**
  pediatric depression, 48, 51, 52
  post-recovery deficits, 111
  predictive validity, 3, 4, 15
  primary care clinician–patient relationship, **42**
  progressive cognitive deficits, 119
  three-component model, 6
  treatment interventions, 275
  tricyclic antidepressants, 117
  see also cold cognition
exercise, **286**, 321–323, 334
  acute exercise effects, 323–325, 328–329
  chronic exercise effects, 325–327, 329–331
  evidence-based studies, 323, 333
  functional mechanisms, 327–331
  pediatric depression, 56
  treatment interventions, 281, 282, **284**–**285**
  WHO recommendations, 322
experiment effects, measures of cognitive dysfunction, 236
explicit (declarative) memory, 112, 181
eye-tracking
  pediatric depression, 52
  social and emotional processing, 83

FA (fractional anisotropy), 64, 65, 66
Faces Pain-Rating Scale (FPRS), 38
facial processing, 92, 93–95, 265
  case-control studies, **96**–**99**, **101**
  emotion perception, 262–264
  negative bias, 83, 154
  novel/fast-acting medication, 75
  pediatric depression, 53
  and severity of depression, **103**–**105**
  see also social cognition
false positive classification, cognitive dysfunction, 20, 21
familial studies, 149. *see also* twin studies
far transfer, cognitive remediation, 266
fast-acting medication, 75
fatigue, and cognitive dysfunction, 18, 19, **19**
fear conditioning, amygdala, 168
feedback mechanisms, HPA axis, **180**. *see also* homeostasis
fight or flight response, 72, 214
first episodes of MDD, biomarkers, 148
FKBP5 gene, 183
flexibility. *see* cognitive flexibility; neuroplasticity
fMRI. *see* functional magnetic resonance imaging
FOCUS study, 238, **238**
forced choice paradigm, 231
FPRS (Faces Pain-Rating Scale), 38
fractional anisotropy (FA), 64, 65, 66
frontal cortex, 63. *see also* prefrontal cortex
frontal lobes, white matter tracts, 200
fronto-cingulate cortex, pediatric depression, 52
fronto-striato-limbic white matter tracts, 200
functional connectivity analysis, default mode network, 218, **219**
functional magnetic resonance imaging (fMRI)
  neural circuits, 197
  pediatric depression, 52
  social exclusion, 88
functional outcomes and recovery, 125, 126, 128, 140, 161
  assessment, 128, 135
  attention and processing speed, 260
  clinical implications, 139–141
  cognitive dysfunction, 70, 110, 128, **129**–**134**
  emotion distortion and biases, 265–266
  emotion perception, 263
  neuroscience of, 257–258
  occupational functioning, 135–137. *see also* employment status
  primary care, 30, 31
  and progressive cognitive deficits, 119
  quality of life, 137–138
  social cognition, 93, 95–100, 106
  subjective measures, **243**
  working memory and executive function, 262
  see also psychosocial functioning; remission

Gage, Phineas, 200
gamma aminobutyric acid (GABA), 18, 195
gaze behavior. *see* eye-tracking
gender effects, cognitive deficits, 117
genetics
  antecedents to illness, 112
  biomarkers of illness, 146, 147, 153, 169
  familial studies, 149
  HPA axis stress response, 183–184, 185
  predicting future depression, 6–8
  serotonin transporter gene, 74
  white matter neurobiology, 195–196
  see also endophenotypes
glial cells, 61, 62, 65
  cytokine model, 167
  pathology of white matter, 195
  progressive cognitive deficits, 117
Global Severity Index, psychological functioning, 5, **10**
glucocorticoids/glucocorticoid receptors, 162, 180, 181, 183, 185
glucose metabolism, 61, 63. *see also* insulin resistance
glutamate neurotransmission, 61, 195
glycogen synthase kinase 3 beta (GSK3β), 293
goal-setting, cognitive remediation, 317, 318
gold standard measures
  cognitive remediation, 306
  neuropsychological assessment as, 244
  and subjective measures, 250

© in this web service Cambridge University Press www.cambridge.org

CAMBRIDGE

Cambridge University Press
978-1-107-07458-3 - Cognitive Impairment in Major Depressive Disorder: Clinical Relevance, Biological Substrates and Treatment Opportunities
Edited by Roger S. McIntyre
Index
More information

Go/NoGo task, 232
  exercise, 333
  pediatric depression, **49**–**50**, 50, 51
gray matter, 62, 63, 66
group therapy, 100

Hamilton Depression Rating Scale (HDRS), **9**
"hate circuit" (white matter tracts), 197
health-related quality of life. *see* quality of life
heritability, 7, 153. *see also* genetics
HIF (hypoxia inducible factor), 290
hippocampus/hippocampal volume, 60
  anatomy, 62–63, 63
  antidepressant medication, 119
  biological mechanisms of MDD development, 5–6
  biomarker for response to treatment, 63
  biomarkers of illness, 148, 152
  erythropoietin, 290, 291, 294, **295**–**296**, 297, **298**
  exercise effects, 329–331, 332–333
  insulin resistance, 209, 211, 215–217, **217**, **218**
  neural connectivity, 220. *see also* default mode network
  pathology of white matter, 195
  progressive cognitive deficits, 116–117
  rumination, 202–203
  stress effects, 153, 180–182
  see also long-term potentiation
holistic treatment interventions, 76. *see also* multi-modal approaches
HOMA-IR, 216–217, **217**, **218**. *see also* insulin resistance
homeostasis
  calcium, 210
  endocrine, 209
  HPA axis, **180**, 182
  and threat of social rejection, 87
homework, cognitive remediation, 312, **313**
hospitalizations, number of lifetime depressive episodes, 113–118
hot cognition, 1, 257
  biological mechanisms of MDD development, 6
  biomarkers of illness, 154
  clinician–patient relationship, 41, **41**
  cognitive alterations during course of illness, 69–73
  combination treatments, 274
  deep brain stimulation, 76
  erythropoietin, 297
  insomnia comorbidity, 40
  mindfulness-based meditation processes, 283
  neural circuits, 70
  neuroanatomy, 60
  novel/fast-acting medication, 76
  objective measures, 35
  pediatric depression, 48
  screening tools in primary care, 32, **33**
  as state biomarkers, 70
  see also emotion(s)/emotional processing
HPA axis. *see* hypothalamic–pituitary–adrenal (HPA) axis
hypercortisolism, 179, 182
  antecedents to illness, 112
  biological mechanisms of MDD development, 5–6
  insulin resistance, 214
  post-recovery deficits, 111
  progressive cognitive deficits, 117
hyperreactivity, neural networks, 268
  default mode network, 267
  emotion perception, 263
  prefrontal cortex, 259
  working memory and executive function, 261–262
hypocortisolism, bipolar disorder, 184
hyporeactivity, neural networks, 268
  default mode network, 267
  emotion perception, 263
  prefrontal cortex, 259
hypothalamic–pituitary–adrenal (HPA) axis, 179, 181, 188
  biological mechanisms of MDD development, 5
  bipolar disorder, 184–185, **186**
  cognition, 180, 185, **186**
  cytokine model, 162, 165
  future directions for study, 187
  homeostasis, **180**, 182
  insulin resistance, 210, 211, 213
  measures of activity, 180
  neurobiological effects, 187
  progressive cognitive deficits, 117, 162
  receptors. *see* glucocorticoid receptor; mineralocorticoid receptor
  social exclusion, 86, **87**
  stress response, 153, 179, 182, 183
hypoxia, erythropoietin, 290
hypoxia inducible factor (HIF), 290

IAPS (International Affective Picture System), 297
IGT (Iowa Gambling Task), **49**–**50**, 50, 51
IMDCP (International Mood Disorders Collaborative Project), 280
immune dysregulation, 86, 161, **170**. *see also* inflammation
incidence. *see* epidemiology
indications for cognitive assessment, 35–37
individual-level measures of variation, cognitive dysfunction and change, 20, **21**, **22**, 24–26
inflammation, 160, 169–170
  amygdala, 165, 168–169
  chronic exercise effects, 330
  emotional regulation, 165, 168, **170**
  HPA axis, 187
  molecular mechanisms, 165
  neurobiology, 161–163
  neurodegenerative effects, 166–168
  pathology of white matter, 195
  staging model, 163–165, **163**, **164**
infliximab, 162
inhibition, emotional/behavioral. *see* response inhibition
insomnia, 39–40, 185, 265
Insomnia Severity Index, 40
insula, 86, 263
insulin resistance, 209–211, 220
  and brain function, 211, 215–217
  cognitive impairment, 214–215
  default mode network, 217–219, **219**, **220**
  etiology, 213–214
  hippocampal volume, 215–217, **217**, **218**
  and major depressive disorder, 211–213
insulin treatment, 282–283, **284**–**286**
insulin-like growth factor 1 (IGF-1), 329, 333
integrated models, 265
intelligence quotient. *see* IQ
interferon, 165, 166–167
interleukins, 165, 166–167, 168–169
International Affective Picture System (IAPS), 297
International Mood Disorders Collaborative Project (IMDCP), 280
interpersonal interactions, and MDD, 92. *see also* social cognition
interventions. *see* treatment interventions
introspection, measures of cognitive dysfunction, 235
Iowa Gambling Task (IGT), **49**–**50**, 50, 51
IQ (intelligence quotient)
  cognitive remediation, 310
  cognitive reserve, 3
  predicting future depression, **9**–**11**, 71
irritability, in youth depression, 47

© in this web service Cambridge University Press www.cambridge.org

CAMBRIDGE

Cambridge University Press
978-1-107-07458-3 - Cognitive Impairment in Major Depressive Disorder: Clinical Relevance, Biological Substrates and Treatment Opportunities
Edited by Roger S. McIntyre
Index
More information

ketamine, 24, 75–76
ketoconazole, 188
kindling effect, progressive cognitive deficits, 120

late-onset MDD
  biomarkers of illness, 151
  neurotoxicity hypothesis, 113
  vascular hypothesis, 194–195
  see also age of onset
learning, 1
  cytokine effects, 165–166
  objective measures, **36**
  see also cold cognition; memory
length of the depressive episodes. *see* duration of illness
life satisfaction. *see* quality of life
limbic cortex
  anatomy, 63
  insulin resistance, 209
  progressive cognitive deficits, 116–117
lipids, blood, 210, 213, 214–215
lisdexamfetamine, **284–285**
Longitudinal Interval Follow-up Evaluation–Range of Impaired Functioning Tool (LIFE–RIFT), 136, 138–139
longitudinal studies
  biomarkers of illness, 150–151
  cognitive dysfunction in MDD, 242
  functional outcomes, **129**
  neurotoxicity hypothesis, **114–115**
  pediatric depression, 54–55
  predicting future depression, 2–3, **8–11**
  white matter integrity, 65
long-term potentiation (LTP), 289
  chronic exercise effects, 329–330
  insulin resistance, 211
  cytokine effects, 166
  see also brain-derived neurotrophic factor
low positive affect, 83. *see also* negative cognitive bias

magnetic resonance imaging (MRI), 61, 116, 147–148
maintenance treatment, youth depression, 47–48
major depressive disorder (MDD)
  age of onset, 1
  cognitive dysfunction in, **243**, 244
  DSM criteria, 15
  incidence and prevalence, 1, 15
  interpersonal interactions, 92. *see also* social cognition
  protective factors, 3
maladaptive strategies, pruning, 308. *see also* cognitive remediation
maladaptive thought processes, 154. *see also* negative cognitive bias
managing symptoms
  primary care, 30–32, 41–43
  progressive cognitive deficits, 118–120
  see also treatment interventions
MAPK (mitogen-activated protein kinase) pathway, 169
Massachusetts General Hospital Cognitive and Physical Functioning Questionnaire, 35, 247–248, **251–252**
MATRICS Consensus Cognitive Battery (MCCB), 237
McGill Pain Questionnaire, 38–39
MDD. *see* major depressive disorder
measurement of cognitive dysfunction and change, 15–16, **17**, 70, 229, 239–240
  cognitive deficits in MDD, 232–233, **234**
  cognitive domains, 232
  computerized, 126
  data analysis, 237–239
  FOCUS study, 238
  functional outcomes, 135
  indications, primary care, 35
  individual-level measures of variation, 20–22, **21**, 25, 26
  practice effects, 24–25
  predictive validity, 15, **17**
  primary care, 32–35, **33**
  repeated assessment, 235–237
  responses to treatment interventions, 22–24
  screening, 233–235
  social cognition, 102–106
  socially relevant benchmarks, 17–20, **17**, **18**
  subjective and objective ratings, 245–247, **246**
medial prefrontal cortex (MPFC)
  rumination, 202–203
  self-focus, 84–85
medical comorbidity. *see* comorbidity
Medical Outcomes Study, 127, 250
medication, **278**, 281
  anatomy of brain, 63–64
  benzodiazepines, 40, 118
  cognitive remediation interactions, 318
  confounding factors, 62–63, 117–118
  cortisol lowering, 182–183
  efficacy prediction, 257
  novel, 75, 76. *see also* erythropoietin
  progressive cognitive deficits, 117
  psychostimulants, 280–281, 283. *see also* modafinil
  see also antidepressant medication; *specific drugs by name*
meditation, mindfulness-based, 283
memory, 1, 6
  bias, 202–203, 265, 268–269. *see also* negative cognitive bias
clinician–patient relationship, **42**
cytokine effects, 166
erythropoietin, 290, 291–293, **294–295**, **298**, 299, **301**
  and functional outcomes, **129–134**, 135
  HPA axis stress response, 180–182
  insulin resistance, 209, 211
  measures, 231, 231–232
  negative bias, 32
  neural circuits, 200–201, 202
  pediatric depression, 55
  predictive validity, **17**
  spatial, **147**
  see also cold cognition; declarative memory; episodic memory; working memory
mental processing speed. *see* processing speed
mentalizing network, 82
meta-analyses, 15, 20, 23
  age of illness onset, 113
  anatomy of brain, 63
  biomarkers of illness, 148
  cytokine model, 167
  emotion perception, 263–264
  exercise, 323–327, 331–334
  eye-tracking, 83
  neural circuits, 198
  novel/fast-acting medication, 281
  post-recovery deficits, 111
  salience network, 268
  working memory and executive function, 261
metabolic syndrome, 210. *see also* insulin resistance
metacognition, 308, 309
methylphenidate, 75
metyrapone, 182–183
microglia, 61–62, 167
mifepristone, 185, 188
mild cognitive impairment, 120, 235
mindfulness-based meditation processes, 283
mineralocorticoid receptor (MR), 179–180, 183, 184–185
Mini Mental State Exam (MMSE), 2, **8–11**, 35, 233, 244
MiniCog, 35
mirror neural system (MNS), 82
mirtazapine, 213, 276, **284–285**
mitogen-activated protein kinase (MAPK) pathway, 169
modafinil (Provigil), 75, 280–281, 283
molecular mechanisms, inflammation, 165
monitoring of cognitive processes (metacognition), 308, 309
monitoring technology, biomarkers of illness, 74

© in this web service Cambridge University Press www.cambridge.org

CAMBRIDGE

Cambridge University Press
978-1-107-07458-3 - Cognitive Impairment in Major Depressive Disorder: Clinical Relevance, Biological Substrates and Treatment Opportunities
Edited by Roger S. McIntyre
Index
More information

monoamines, HPA axis, 187
Montreal Cognitive Assessment (MoCA), 35, 233
motivational issues, cognitive remediation, 317–318
MR. *see* mineralocorticoid receptor
MRI. *see* magnetic resonance imaging
Multidimensional Scale of Independent Functioning (MSIF), 128
multi-modal approaches, 40–41, 75, 76. *see also* treatment interventions
multiple sclerosis, 34, 201, 245, 293, **301**

National Adult Reading Test (NART), 234–235
National Comorbidity Survey Replication (NCS-R), 127
n-back test, **36**, 276
NEAR (Neuropsychological and Educational Approach to Remediation), 310
near transfer, cognitive remediation, 266
needs, fundamental, 86
negative automatic thoughts, 154
negative cognitive bias, 264
  biological mechanisms of MDD development, 5–6
  biomarkers of illness, 74, 149, 153
  clinician–patient relationship, 41, **42**
  cognitive model of depression, 258
  cognitive remediation, 308, 315–316
  emotion perception, 262–263
  and emotional bias, 1, 83–84, 202, 264
  erythropoietin, 294
  hot cognition, 72
  memory, 202, 265, 268–269
  neural circuits, 196–197, 203
  and self-focus, 84
  see also catastrophizing
negative feedback, catastrophic response to, 72
neural circuits (white matter tracts), 198
  attention, 199, 201–202
  executive function, 199–200
  hot vs. cold cognition, 70
  memory, 200–201, 202
  negative cognitive bias, 203
  processing speed, 198–199
neural connectivity
  antecedents to illness, 112
  biomarkers of illness, 153
  exercise effects on cognition, 329–331
  psychotherapy, 120
  stress effects, 153
neural modulation, 266
neural networks. *see* cognitive control network; default mode network; emotion network; hyperreactivity; hyporeactivity; neural connectivity
neuroanatomy, 62–63, 63–64, 66, 116–117
neurobiology of depression, 81, 161–163, 187
neurocognitive model of depression, **73**
neurodegenerative disorders, 65, 166–167, 214
neurodevelopment, and erythropoietin, 290
neurodevelopmental abnormalities
  antecedents to illness, 3–5
  biological mechanisms of MDD development, 5–6
  biomarkers of illness, 152
  predicting future depression, **8–11**
  white matter integrity, 64–65
neuroendocrine malfunction, 161–163
neurogenesis
  cytokine models, 166
  erythropoietin, 290
  HPA axis, 187
  insulin treatment, 282–283
neuroimaging
  antecedents to illness, 110
  biomarkers of illness, 146, 147–148
  post-recovery deficits, 111
  social and emotional processing, 83
  white matter neurobiology, 196
  see also specific modalities
neuromodulatory treatment interventions, 274. *see also* neurostimulation
neuroplasticity
  antecedents to illness, 112
  cytokine model, 161–163, 166
  erythropoietin, 289
  exercise effects, 329–331
  inducing, 306, 307. *see also* cognitive remediation
  insulin treatment, 282–283
  progressive cognitive deficits, 121
  see also brain-derived neurotrophic factor; cognitive flexibility
neuroprogression models, 52, 56, 162. *see also* neurotoxicity hypothesis; progressive cognitive deficits
neuroprotection, 165, 166–167
  erythropoietin, 289, 290, **292**
  glial cells, 167–168
neuropsychological assessment
  as gold standard, 244
  snapshot assessments, 245
Neuropsychological and Educational Approach to Remediation (NEAR), 310
neuropsychological model of depression, 149, **150**
Neuropsychological Test Battery (NTB), 238
neuroscience of functional outcomes, 260, 268–269
  attention and processing speed, 260
  emotion distortion and biases, 264
  emotion network, 258, 267–268
  emotion perception, 264
  future perspectives, 269
  intervention targets, 268
  salience network, 258, 268
  working memory and executive function, 260–261
  see also cognitive control network; default mode network
neurostimulation, 281. *see also* deep brain stimulation; neuromodulatory treatment interventions; repetitive transcranial magnetic stimulation; transcranial direct current stimulation
neurotoxicity hypothesis, 110, 118, 119
  biomarkers of illness, 151
  longitudinal studies, **114–115**
  see also neuroprogression models; number of lifetime depressive episodes
neurotransmitter uptake, cellular anatomy, 61–62
neurotrophic factors, 289. *see also* brain-derived neurotrophic factor
nitrosative stress, 161–163, 293
NMDA (*N*-methyl-D-aspartate) receptor antagonists, 75, 290
norepinephrine (noradrenaline)
  exercise effects, 329–331
  hippocampal formation, 119
  insulin resistance, 210
novel medication, 75. *see also* erythropoietin
NR3C1 (glucocorticoid receptor gene), 184, 185
NTB (Neuropsychological Test Battery), 238
nucleus acumbens, 54–55
number of lifetime depressive episodes
  biomarkers of illness, 152
  clinical outcomes, 73–74, 140
  exercise effects, 330–331
  neurotoxicity hypothesis, **114–115**, 118
  post-recovery deficits, 111
  see also duration of illness

© in this web service Cambridge University Press www.cambridge.org

CAMBRIDGE

Cambridge University Press
978-1-107-07458-3 - Cognitive Impairment in Major Depressive Disorder: Clinical Relevance, Biological Substrates and Treatment Opportunities
Edited by Roger S. McIntyre
Index
More information

obesity, 210. *see also* insulin resistance
objective cognitive measures, 233, 235
  primary care, **36**
  vs. subjective measures, 244–245
occupational functioning. *see* employment status
off-line social processes, social cognition, 82
oligodendrocytes, 61, 195
on-line social processes, social cognition, 82
orbitofrontal cortex (OFC), 111, 117, 263
other processing, theory of mind, 85
outcomes, clinical, 73, 139. *see also* functional outcomes and recovery
over-general memories, 265, 268–269
oxidative stress, 161, 293
oxytocin, biomarkers of illness, 88

Paced Auditory Serial Addition Test, 309
pain comorbidity, 39
Pain Disability Index, 38
parental depression, children and adolescents, 55
paroxetine, 213, 277
patient education, 32, 42–43
patient engagement, cognitive remediation, 317–318
Patient Health Questionnaire (PHQ-9), 135
Patient Reported Outcome Measurement Information System (PROMIS), 250
patient indications for cognitive assessment, 35
pediatric depression, 47
  cognitive dysfunction studies, **49**–**50**
  executive function/attention, 48–52
  facial processing, 52–53
  future directions for study, 56
  memory, 55
  parental depression, 55
  processing speed, 53–54
  reward processing, 54–55
  social exclusion, 88
  treatment interventions, 47–48, 56
  see also educational functioning
Perceived Deficits Questionnaire (PDQ), 239, **243**, 248–250, **249**, 252–253
  occupational functioning, 135
  primary care use, 30, 32, **33**, 34
persistent cognitive dysfunction. *see* residual cognitive symptoms
pessimism. *see* negative cognitive bias
PFC. *see* prefrontal cortex
pharmacological treatment. *see* medication
phase-specific neuroimmune model of clinical depression, **163**. *see also* staging model of inflammation
Phineas Gage, case of, 199–200
physical abuse, 5–6. *see also* childhood trauma
physical activity, 321. *see also* exercise
PICs. *see* pro-inflammatory cytokines
planning, mental, 232. *see also* executive function
polymorphisms, gene
  biomarkers of illness, 146
  HPA axis stress response, 183–184, 185
  serotonin transporter gene, 74
  white matter pathology, 195–196
  see also genetics
positron emission tomography (PET), 63
post-acute stage of inflammation, 163–165, **163**
post-recovery deficits. *see* residual cognitive symptoms
practice effects, assessment tests, 25, 236–237
precuneus, 52–53
predictions of future depression, 3
  cognitive dysfunction, **17**
  prevention strategies, 6–8
  see also premorbid cognitive function
predictions of treatment response, 260, 261, 262
prednisolone suppression test (PST), 183
prefrontal cortex (PFC), 60
  anatomy, 62–63
  biological mechanisms of MDD development, 6
  hyper or hyporeactivity, 259
  insomnia comorbidity, 40
  neural circuits, 198, 199
  pediatric depression, 52
  reward processing, 54–55
  social and emotional processing, 83
  see also dorsolateral PFC; medial PFC; ventrolateral PFC
premorbid cognitive function, 110
  biomarkers of illness, 147–148, 149
  cold cognitive deficits, 1, **8**–**11**
  neurotoxicity hypothesis, 118
  progressive cognitive deficits, 112
  see also predictions of future depression
prenatal stress, and MDD development, 5–6
prevalence. *see* epidemiology
prevention strategies, 6–8
primary care, 30, 43
  assessment of cognitive impairment, **33**, 37
  comorbidities, 31, 32, 40
  management strategies for impairment, 32
  objective measures, **36**
  treatment interventions/management, **42**, 43
PRMQ (Prospective and Retrospective Memory Questionnaire), 250
problem-solving, 52. *see also* executive function
problem-solving strategies, cognitive remediation, 308
procedural learning, 180–182
processing speed, 1
  age of onset, 113
  biomarkers of illness, **147**
  clinician–patient relationship, **42**
  cytokine effects, 166
  erythropoietin, 290, 299
  and functional outcomes, **129**–**134**, 135, 260
  neural circuits, 198–199
  objective measures, **36**
  pediatric depression, 53–54
  post-recovery deficits, 111
  see also cold cognition; psychomotor speed
prodromal phase of dementia, 120, 235
progressive cognitive deficits, 110, 120–121
  antecedents to illness, 112
  dementia risk, 120
  neurotoxicity hypothesis, **114**, 118
  post-recovery deficits, 110–112
  see also neuroprogression models
pro-inflammatory cytokines (PICs), 163. *see also* cytokine models of depression and cognition; inflammation
PROMIS (Patient Reported Outcome Measurement Information System), 250
prosody, 92, 93, 102, 106. *see also* social cognition
Prospective and Retrospective Memory Questionnaire (PRMQ), 250
protective factors, MDD, 3
proton MRI, 61
Provigil (modafinil), 75, 280–281, 283
pruning maladaptive strategies, cognitive remediation, 308
pseudospecificity of treatment response, cognitive remediation, 318

© in this web service Cambridge University Press www.cambridge.org

CAMBRIDGE

Cambridge University Press
978-1-107-07458-3 - Cognitive Impairment in Major Depressive Disorder: Clinical Relevance, Biological Substrates and Treatment Opportunities
Edited by Roger S. McIntyre
Index
More information

PST (prednisolone suppression test), 183
psychoanalytic-interactional group therapy, 100
psychological interventions. *see* psychotherapy
psychomotor speed
  clinician–patient relationship, 42
  diagnostic criteria, 15
  measures, 230–231
  see also processing speed
psychosocial functioning, 70, 139, 161
  attention and processing speed, 260
  clinician–patient relationship, 43
  emotion perception, 264
  functional outcomes, 125, 126–127
  pediatric depression, 47, 52
  predicting future depression, 1, 4, **8–11**
  and progressive cognitive deficits, 119
  subjective measures, 242, **243**
  see also employment status; social cognition
psychostimulants, 281, 283. *see also* modafinil
psychotherapy, **286**
  cognitive remediation, **314**, 315, **315**, **317**
  cold cognition, 154
  efficacy, 257
  progressive cognitive deficits, 120
  and social cognition, **103**
  see also cognitive behavioral therapy
psychotic features in MDD, 100, **103**, 118

QIDS-SR (Quick Inventory of Depressive Symptomatology), 32, **33**
quality of life, 125, 126, 128, 130, **130**, 137. *see also* functional outcomes and recovery; psychosocial functioning
Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q), 138

RAVLT. *see* Rey Auditory Verbal Learning Test
RBANS (Repeatable Battery for the Assessment of Neuropsychological Status), 136
reappraisal, cognitive, 265
reassurance seeking, 265
reboxetine, 277
recovery. *see* functional outcomes and recovery; remission
recurrence risk
  and cognitive dysfunction, 70
  exercise effects, 331
  progressive cognitive deficits, 118
  see also number of lifetime depressive episodes; risk factors for MDD
red blood cell mass, erythropoietin effects, 294, 299
regional cerebral blood flow. *see* cerebral blood flow
regulation of emotion, 82, **87**, 257, 258. *see also* response inhibition
rejection, social, 81, 86, **87**, 197
relapse rates, 70, 110. *see also* number of lifetime depressive episodes; recurrence risk
relational functioning, 161. *see also* social cognition
reliable change index (RCI), 25
remission
  biomarkers of illness, 148
  post-recovery deficits, 110, 259. *see also* residual cognitive symptoms
  primary care, 31
  working memory, 72
  see also functional outcomes and recovery; state vs. trait cognitive dysfunction
Repeatable Battery for the Assessment of Neuropsychological Status (RBANS), 136
repeated assessment, measures of cognitive dysfunction, 235, 236
repetitive transcranial magnetic stimulation (rTMS), 266
repression, memory, 200
Research Domain Criteria (RDoC), 69
reserve, cognitive, 3. *see also* IQ
residual cognitive symptoms
  biomarkers of illness, 151
  HPA axis, 187
  neuroscience of functional outcomes, 259
  number of lifetime depressive episodes, 113, **114**
  progressive, 110–112. *see also* neuroprogression models
  subjective measures, 243
  see also state vs. trait cognitive dysfunction
RESPECT trial, pain comorbidity, 39
response inhibition
  attention deficit/hyperactivity disorder, 3
  measures of cognitive dysfunction and change, 232
  objective measures, **36**
  pediatric depression, 52, 54
  see also executive function; regulation of emotion
response to treatment, 169, 185, 260
  attention and processing speed, 260
  emotion distortion and biases, 265
  emotion perception, 263
  late-onset MDD, 194
  number of lifetime depressive episodes, 113
  and rumination, 265
  working memory and executive function, 262
resting state network. *see* default mode network
retardation. *see* psychomotor speed
reversible/functional changes, 93, 95, 106. *see also* functional outcomes and functional recovery
reward processing, 54, 72, 84
Rey Auditory Verbal Learning Test (RAVLT), **36**, 135, 138, 238, 277
Rey Complex Figure Test, 138
risk factors for MDD
  ADHD, 3
  antecedents to illness, 113
  biomarkers of illness, 149, 153
  exercise effects, 331
  predicting future depression, 6
  progressive cognitive deficits, 118
  see also number of lifetime depressive episodes; recurrence risk
risk taking, and reward, 72
rumination, 265, 268
  biological mechanisms of MDD development, 5
  biomarkers of illness, 154
  clinician–patient relationship, 41
  cognitive remediation, 309
  default mode network, 267
  emotion distortion and biases, 264
  insomnia comorbidity, 40
  neural circuits, 202
  and self-focus, 84
  and social cognition, 100, **103**
  and suicidal behavior, 265

salience network (SN), 258, 268
salivary cortisol levels, 55, 180, 182
satisfaction with life. *see* quality of life
scar effect, 153, 259. *see also* neurotoxicity hypothesis
SCG. *see* subgenual cingulate cortex
Schedule for Affective Disorders and Schizophrenia for School-Age Children, **9**
schizophrenia
  biomarkers of illness, 153
  cellular anatomy, 61–62
  cognitive dysfunction, 16, 17, **17**, **18**
  cognitive remediation, 266, 306, 319

© in this web service Cambridge University Press www.cambridge.org

CAMBRIDGE

Cambridge University Press
978-1-107-07458-3 - Cognitive Impairment in Major Depressive Disorder: Clinical Relevance, Biological Substrates and Treatment Opportunities
Edited by Roger S. McIntyre
Index
More information

erythropoietin, 293, **300**
social cognition, 92, **96**
working memory, 71
scientific brain training program, 312
screening, 233. *see also* measurement of cognitive dysfunction and change
screening tools
predicting future depression, 6
primary care, 30, 32, **33**
see also specific instruments by name
SDS. *see* Sheehan Disability Scale
selective attention, 258, 259. *see also* attention
selective serotonin reuptake inhibitors. *see* SSRIs
self-control. *see* response inhibition
self-efficacy targeting, cognitive remediation, 315
self-esteem, and social exclusion, 88
self-focus, 84
self monitoring (metacognition), 308, 309
self-reference effect (SRE), word recall, 84
self-referential appraisal, rumination, 203
self-report instruments, 126, 235
functional outcomes, 135
primary care, 34
subjective measures, 244
see also specific instruments by name
SENSO framework, threat of social rejection, 87
Sequenced Treatment Alternatives to Relieve Depression (STAR*D) study, 147, 243–244
serotonin
exercise effects, 328
hippocampal formation, 119
HPA axis, 187
insulin resistance, 210, 211, 213
serotonin reuptake inhibitors. *see* SNRIs; SSRIs
serotonin transporter gene, 74, 146, 169
sertraline, 276, 322
severity of illness, 118
biomarkers of illness, 152
functional outcomes, 126, 127
and rumination, 265
and social cognition, 100, 102, **103**
sexual abuse in childhood, 5. *see also* childhood trauma
SF-12 (12-item Short Form Health Survey), 137
SGC. *see* subgenual cingulate cortex
Sheehan Disability Scale (SDS), 31, 34, 127, 242, **243**
Shipley Institute of Living Scale, 4
short-term memory, 6
Simple Reaction Time (SRT), **36**, 230, 231
simulations, cognitive remediation, **315**
single-nucleotide polymorphisms (SNPs), 146, 195. *see also* polymorphisms
sleeping problems. *see* insomnia
smartphones, monitoring technology, 74
SMILE study (Standard Medical Interventions and Longterm Exercise), 322
snapshot assessments, 245
SNRIs (serotonin norepinephrine reuptake inhibitors), 119, **284**
social cognition, 81, **87**, 92, 102, 106
case-control studies, **96**, **101**
definitions, 102
facial processing, 93
future directions for study, 106
methodological issues, 102
remitted and symptomatic stages, 95, **96**
and severity of depression, 100, 102, **103**
see also psychosocial functioning
social engagement, and cognitive dysfunction, 17, **18**, **19**
social functioning. *see* psychosocial functioning
social perception, 102
social processes, definitions, 82
social rejection, 81, 86, **87**, 197
Social Skills Performance Assessment (SSPA), 139
somatic disorders, 182
spatial memory, **147**
speed vs. accuracy effects, 236. *see also* processing speed
speed of memory scores, 231
SSRIs (selective serotonin reuptake inhibitors), **284**
biomarkers of illness, 151
insulin resistance, 213
novel/fast-acting medication, 75
and progressive cognitive deficits, 119
response to treatment, 260
youth depression, 47
staging model of inflammation, 163
Standard Medical Interventions and Longterm Exercise (SMILE) study, 322
STAR*D (Sequenced Treatment Alternatives to Relieve Depression) trial, 147, 243–244
state vs. trait cognitive dysfunction
biomarkers, 70, **147**, **150**, 151, 152, 154, 160
cold cognition, 70, **71**
endophenotypes, 145, 147
executive function and attention, 111
functional outcomes, 140
post-recovery deficits, 110
primary care, 40
progressive cognitive deficits, 110
reward dysfunction, 54
social cognition, 95, **101**
see also remission; residual cognitive symptoms
Sternberg memory store task, 261
strategy planning, 232. *see also* executive function
stress
antecedents to illness, 112
biological mechanisms of MDD development, 5–6
biomarkers of illness, 152, 153
HPA axis response, 179, 182, 185
neurobiology, 161
progressive cognitive deficits, 117, 119, 120
reward processing, 54
striatum, 196, 263
Stroop Test, **9**
antidepressant medication, 276
exercise, 333
objective measures, **36**
pediatric depression, **49**, 51
predicting future depression, 2
subgenual cingulate cortex (SCG), 53, 63, 149, 197, 263, 267
subjective measures, 242
functional impairment, **243**
incidence and prevalence of dysfunction, **243**
vs. objective measures, 244
psychometrically validated scales, **246**
see also British Columbia Cognitive Complaints Inventory; Massachusetts General Hospital Cognitive and Physical Functioning Questionnaire; Perceived Deficits Questionnaire
sub-syndromal stage, staging model of inflammation, **163**
suicidal ideation, 100, **103**, 161, 257, 265
surveys, occupational functioning, 136
sustained attention, 258, 259, 299. *see also* attention
Symptom Checklist 90-revised, 4, **9**
symptom profiling, 257, 317
symptomatic and remitted stages. *see* state vs. trait cognitive dysfunction

© in this web service Cambridge University Press www.cambridge.org

CAMBRIDGE

Cambridge University Press
978-1-107-07458-3 - Cognitive Impairment in Major Depressive Disorder: Clinical Relevance, Biological Substrates and Treatment Opportunities
Edited by Roger S. McIntyre
Index
More information

symptoms, 32
  changes during course of illness, 69
  primary care, 30, 41
  progressive cognitive deficits, 118
  severity. *see* severity of illness
  youth depression, 47
  see also managing symptoms
synaptic development, cellular anatomy, 61
Syndrome X, 210. *see also* insulin resistance
synergistic effects, catecholamines, 119

technology, monitoring, 74
temporal lobe, 117
thalamus, 149, 202
theory of mind, 85, 92, 93, 95. *see also* social cognition
therapeutic relationship, primary care, 41
THINC group, 35, 239
threat of social rejection (TSR), 87
three-component model of executive function, 6
TNFα (tumor necrosis factor), 165, 166, 169
"to-be-remembered-items" (TBRI), 231
top-down processes
  biological mechanisms of MDD development, 5
  biomarkers of illness, 154
  cold cognition as, 70, 73
  emotional regulation, 197
total lifetime illness. *see* duration of illness; number of lifetime depressive episodes
Tower of Hanoi task, 232
Tower of London planning task, 73
Trail Making Test (TMT), **9**, 232, 239
  antidepressant medication, 276
  functional outcomes, 135
  number of lifetime depressive episodes, 116
  objective measures, **36**
  predicting future depression, 2
trait deficits. *see* state vs. trait cognitive dysfunction
transcranial direct current stimulation (tDCS), 266
transfer, cognitive remediation, 307, 308
transnosographic scar, cognitive dysfunction as, 153, 259. *see also* neurotoxicity hypothesis
trauma. *see* childhood trauma; stress
TRD. *see* treatment-resistant depression
treatment interventions, 23, 274, 283
  cognitive remediation, 282, **284**
  compliance. *see* adherence to treatment
  dietary factors, **284**
  efficacy, 119, 257, **282**, **284**
  exercise, 281, **284**
  functional outcomes, 139, 268
  guiding principles, 275
  holistic approaches, 76
  HPA axis, 187
  insomnia comorbidity, 40
  insulin treatment, 282, **284**
  multi-modal approaches, 40
  neuromodulatory, 274
  neurostimulation, 281. *see also* deep brain stimulation
  pain comorbidity, 39
  pediatric depression, 47, 56
  pharmacotherapy, 275, **278**. *see also* antidepressant medication
  primary care, 32, **42**
  see also behavioral treatment interventions; early intervention; erythropoietin; managing symptoms; multi-modal approaches; psychotherapy; response to treatment
treatment-resistant depression (TRD)
  cognitive remediation, 312, **313**
  erythropoietin, 299, **300**
tricyclic antidepressants, 117, 283
tryptophan, 328. *see also* serotonin
TSR (threat of social rejection), 87
tumor necrosis factor (TNFα), 165, 166, 169
12-item Short Form Health Survey (SF-12), 137
twin studies, **9**
  antecedents to illness, 112
  cognitive deficit biomarkers of illness, 147
  predicting future depression, 2
  see also genetics

unipolar depression, HPA axis, 182–184. *see also* major depressive disorder
University of California San Diego Performance-Based Skills Assessment (UPSA), 279
updating of new information, three-component model, 6

vascular dementia, insulin resistance, 214
vascular endothelial growth factor (VEGF), 329–330, 333
vascular hypothesis
  late-onset MDD, 113
  white matter neurobiology, 194–195
venlafaxine, 47
ventrolateral prefrontal cortex (VLPFC), 86, **87**, 111, 201
ventromedial frontal cortex, 93, 263–264
verbal impairments, 259, 261
  erythropoietin, 294, 297, 299
  and functional outcomes, **129**–**134**, 138
  pediatric depression, **49**–**50**, 51, 55
  word recall, 2, 84
vigilance, biomarkers of illness, 150–151
visual memory, biomarkers of illness, **147**
vortioxetine, 75, 277–280, **278**, 283, **284**
  biomarkers of illness, 151
  cognitive dysfunction and change, 23
  cognitive remediation interactions, 318
vulnerability to MDD, 110, 147–148, 149. *see also* premorbid cognitive functioning

WCST. *see* Wisconsin Card Sorting Test
Wechsler Adult Intelligence Scale (WAIS), 230, 261
Wechsler Intelligence Scale for Children (WISC), 4, 53
Wechsler Memory Scale (WMS), 116, 135, 276
weight gain, antidepressant medication, 213
white matter hyperintensities (WMH), 195
white matter (WM) neurobiology, 195, 203
  attention, 199, 201–202
  executive function, 199–200
  genetics, 195–196
  memory, 200–201, 202
  negative cognitive bias, 201–203
  neural circuits, 196–198
  neuroanatomy, 64–65, 66
  neuroimaging, 196
  pathology, 195
  processing speed, 198–199
  vascular depression hypothesis, 194–195
  see also neural circuits (white matter tracts)
WHO Disability Assessment Schedule, 135
WHO World Health Survey (WHS) study, 127
Wide Range Achievement Test-Revised, 4
Widespread Pain Index, 39
WISC. *see* Wechsler Intelligence Scale for Children

© in this web service Cambridge University Press www.cambridge.org

CAMBRIDGE

Cambridge University Press
978-1-107-07458-3 - Cognitive Impairment in Major Depressive Disorder: Clinical Relevance, Biological Substrates and Treatment Opportunities
Edited by Roger S. McIntyre
Index
More information

Wisconsin Card Sorting Test (WCST), 148, 232, 276
WMS (Wechsler Memory Scale), 116, 135, 276
word recall, 2, 84. *see also* verbal impairments
Work and Social Adjustment Scale (WSAS), 35
work functioning. *see* employment status
Work Limitations Questionnaire (WLQ), 135, 280
Work Productivity and Activity Impairment (WPAI), 243, **243**
working memory, 1
  cold cognition, 70–72
  definitions, 260–261
  exercise, 325
  functional outcomes, 260–262
  measures, 229–230, 231–232
  novel/fast-acting medication, 75
  number of lifetime depressive episodes, 116
  objective measures, **36**
  pediatric depression, 48, 51, 55
  predicting future depression, 3–5, **17**
  three-component model of executive function, 6
  treatment interventions, 275–276
  see also cold cognition
World Health Organization, 128, 135, 322
WSAS (Work and Social Adjustment Scale), 35

years of education (YoE), 234
youth depression. *see* pediatric depression

© in this web service Cambridge University Press www.cambridge.org